-
1
-
-
0031836107
-
Health economics and cost implications of anxiety and other mental disorders in the United States
-
Rice DP, Miller LS. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry 1998; 173 (suppl 34):4-9
-
(1998)
Br J Psychiatry
, vol.173
, Issue.34 SUPPL.
, pp. 4-9
-
-
Rice, D.P.1
Miller, L.S.2
-
3
-
-
0028114056
-
Cost of anxiety disorders: Impact of comorbidity
-
Souetre E, Lozet H, Cimarosti I, et al. Cost of anxiety disorders: impact of comorbidity. J Psychosom Res 1994;38(suppl 1):151-160
-
(1994)
J Psychosom Res
, vol.38
, Issue.1 SUPPL.
, pp. 151-160
-
-
Souetre, E.1
Lozet, H.2
Cimarosti, I.3
-
4
-
-
0030050976
-
Comorbidity of DSM-III-R major depressive disorder in the general population: Results from the US National Comorbidity Survey
-
Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry 1996;168(suppl 30):17-30
-
(1996)
Br J Psychiatry
, vol.168
, Issue.30 SUPPL.
, pp. 17-30
-
-
Kessler, R.C.1
Nelson, C.B.2
McGonagle, K.A.3
-
5
-
-
0028156958
-
Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
-
Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
-
(1994)
Arch Gen Psychiatry
, vol.51
, pp. 8-19
-
-
Kessler, R.C.1
McGonagle, K.A.2
Zhao, S.3
-
7
-
-
52549115724
-
Anxiety algorithm
-
Primary Care Version. Washington, DC: American Psychiatric Association
-
American Psychiatric Association. Anxiety algorithm. In: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Primary Care Version. Washington, DC: American Psychiatric Association; 1995:47-63
-
(1995)
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
, pp. 47-63
-
-
-
8
-
-
0027213217
-
Use of benzodiazepines in anxiety disorders
-
Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. NEnglJMed 1993;328:1398-1405
-
(1993)
NEnglJMed
, vol.328
, pp. 1398-1405
-
-
Shader, R.I.1
Greenblatt, D.J.2
-
10
-
-
0028898694
-
Diagnostic dilemmas presented by patients with anxiety and depression
-
Goldberg RJ. Diagnostic dilemmas presented by patients with anxiety and depression. Am J Med 1995;98:278-284
-
(1995)
Am J Med
, vol.98
, pp. 278-284
-
-
Goldberg, R.J.1
-
11
-
-
0023886671
-
Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial, 1: efficacy in shortterm treatment
-
Ballenger JC, Burrows GD, DuPont RLJ, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, 1: efficacy in shortterm treatment. Arch Gen Psychiatry 1988;45:413-422
-
(1988)
Arch Gen Psychiatry
, vol.45
, pp. 413-422
-
-
Ballenger, J.C.1
Burrows, G.D.2
Dupont, R.L.J.3
-
12
-
-
0003167251
-
The uses of buspirone in psychiatry
-
Sussman N. The uses of buspirone in psychiatry. J Clin Psychiatry Monograph 1994;12(1):3-19
-
(1994)
J Clin Psychiatry Monograph
, vol.12
, Issue.1
, pp. 3-19
-
-
Sussman, N.1
-
13
-
-
52549129916
-
Treatment of panic disorder with serotonin reuptake inhibitors (SSRIs)
-
den Boer JA, Montgomery SA, eds. Chichester, NY: JohnWiley & Sons;
-
Ballenger J. Treatment of panic disorder with serotonin reuptake inhibitors (SSRIs). In: den Boer JA, Montgomery SA, eds. SSRIs in Depression and Anxiety. Chichester, NY: JohnWiley & Sons; 1998:115-134
-
(1998)
SSRIs in Depression and Anxiety
, pp. 115-134
-
-
Ballenger, J.1
-
14
-
-
0029094582
-
Sertraline for social phobia: A double-blind, placebo-controlled crossover study
-
Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995; 152:1368-1371
-
(1995)
Am J Psychiatry
, vol.152
, pp. 1368-1371
-
-
Katzelnick, D.J.1
Kobak, K.A.2
Greist, J.H.3
-
15
-
-
0032569245
-
Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial
-
Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.JAMA 1998;280:708-713
-
(1998)
JAMA
, vol.280
, pp. 708-713
-
-
Stein, M.B.1
Liebowitz, M.R.2
Lydiard, R.B.3
-
16
-
-
0031984862
-
Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder
-
Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998;155:36-42
-
(1998)
Am J Psychiatry
, vol.155
, pp. 36-42
-
-
Ballenger, J.C.1
Wheadon, D.E.2
Steiner, M.3
-
17
-
-
0032751401
-
Current treatments of the anxiety disorders in adults
-
Baljenger JC. Current treatments of the anxiety disorders in adults. Biol Psychiatry 1999;46:1579-1594
-
(1999)
Biol Psychiatry
, vol.46
, pp. 1579-1594
-
-
Baljenger, J.C.1
-
18
-
-
0031900040
-
A meta-analysis of eight randomized, double-blind, control ep clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety
-
Fawcell J, Barkin RL. A meta-analysis of eight randomized, double-blind, control ep clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998;59:127
-
(1998)
J Clin Psychiatry
, vol.59
, pp. 127
-
-
Fawcell, J.1
Barkin, R.L.2
-
19
-
-
0031029632
-
Mirtazapine: An antidepressant with noradrenefgic. and serotonergic effects
-
Stinime KGL, Donheidede JA, Stahl SM. Mirtazapine: an antidepressant with noradrenefgic. and serotonergic effects. Pharmacotherapy 1997; 17:10-21
-
(1997)
Pharmacotherapy
, vol.17
, pp. 10-21
-
-
Stinime, K.G.L.1
Donheidede, J.A.2
Stahl, S.M.3
-
20
-
-
0028919350
-
Focus on nefazodone: A serotonergic drug for major depression
-
Dopheide JA, Stilruner DD. Focus on nefazodone: a serotonergic drug for major depression: Formulary 1995;30:205-210, 212
-
(1995)
Formulary
, vol.30
, pp. 205-210
-
-
Dopheide, J.A.1
Stilruner, D.D.2
-
21
-
-
0034044185
-
Efficacy of extended-release venlafaxine in nondepressed outpatigats iiyith generalized anxiety disorder
-
Rickels K, Pollack MH, Sheehtn-bv, -et al. Efficacy of extended-release venlafaxine in nondepressed outpatigats iiyith generalized anxiety disorder. Am J Psychiatry 2000; 157:968-97
-
(2000)
Am J Psychiatry
, vol.157
, pp. 968-997
-
-
Rickels, K.1
Pollack, M.H.2
Sheehtn-bv3
-
22
-
-
0032869591
-
Efficacy, safety, and tolerability of venlafaxine extended release and buspiijohe in outpatients with generalized anxiety disorder
-
Davidson JRT, DuPont RL, Hedges D.et al\Efficacy, safety, and tolerability of venlafaxine extended release and buspiijohe in outpatients with generalized anxiety disorder. J Clin Psychiatry 1960:528-535
-
(1960)
J Clin Psychiatry
, pp. 528-535
-
-
Davidson, J.R.T.1
Dupont, R.L.2
Hedges, D.3
-
23
-
-
52849106652
-
VentafaxinieXXR is effective for the short- And long-term treatment of generalzed anxiety disorder [poster]
-
Hamburg, Germany
-
Haskins JT, Rudolph R, Aguiar L, et al. VentafaxinieXXR is effective for the short- and long-term treatment of generalzed anxiety disorder [poster]. Presented at the 11th World Congress of Psychiatry; Aug 6-11, 1999; Hamburg, Germany 4.
-
(1999)
Presented at the 11th World Congress of Psychiatry; Aug 6-11
, pp. 4
-
-
Haskins, J.T.1
Rudolph, R.2
Aguiar, L.3
-
24
-
-
4243416162
-
Dose-response efficacy of long-term treatment of venlafaxine extended-release in generalized anxiety disorder [abstract]
-
Hackett D, Desmet A, Saunas EO. Dose-response efficacy of long-term treatment of venlafaxine extended-release in generalized anxiety disorder [abstract]. Eur Neuropsychopharmacol 1999;9(suppl 5):S315
-
(1999)
Eur Neuropsychopharmacol
, vol.9
, Issue.5 SUPPL.
-
-
Hackett, D.1
Desmet, A.2
Saunas, E.O.3
-
25
-
-
0242588732
-
Venlafaxine XR is an efficacious short- And long-term treatment for generalized anxiety disorder
-
Oct 31-Nov 4, Paris, France
-
Haskins JT, Rudolph R, Aguiar L, et al, for the Venlafaxine XR 218 Study Group. Venlafaxine XR is an efficacious short- and long-term treatment for generalized anxiety disorder. Presented at the 11 th annual congress of the European College of Neuropsychopharmacology; Oct 31-Nov 4, 1998; Paris, France
-
(1998)
11 Th Annual Congress of the European College of Neuropsychopharmacology
-
-
Haskins, J.T.1
Rudolph, R.2
Aguiar, L.3
-
26
-
-
0006822948
-
Dose-response efficacy of venlafaxine XR in GAD [poster]
-
Aug 6-11, Hamburg, Germany
-
Hackett D, Desmet A, Saunas EO. Dose-response efficacy of venlafaxine XR in GAD [poster]. Presented at the 11th World Congress of Psychiatry; Aug 6-11, 1999; Hamburg, Germany
-
(1999)
11th World Congress of Psychiatry
-
-
Hackett, D.1
Desmet, A.2
Saunas, E.O.3
-
27
-
-
0029555176
-
Venlafaxine in social phobia
-
Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull 1995;31: 767-771
-
(1995)
Psychopharmacol Bull
, vol.31
, pp. 767-771
-
-
Kelsey, J.E.1
-
28
-
-
0029099365
-
Venlafaxine treatment of panic disorder: A case series
-
Geracioti TD Jr. Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry 1995;56:408-410
-
(1995)
J Clin Psychiatry
, vol.56
, pp. 408-410
-
-
Geracioti Jr., T.D.1
-
29
-
-
0030074946
-
Open treatment of obsessivecompulsive disorder with venlafaxine: A series of ten cases [letter]
-
Rauch SL, OSullivan RL, Jenike MA. Open treatment of obsessivecompulsive disorder with venlafaxine: a series of ten cases [letter]. J Clin Psychopharmacol 1996;16:81-84
-
(1996)
J Clin Psychopharmacol
, vol.16
, pp. 81-84
-
-
Rauch, S.L.1
Osullivan, R.L.2
Jenike, M.A.3
-
30
-
-
0031963340
-
The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: A dose-response study
-
Khan A, Upton GV, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol 1998;18:19-25
-
(1998)
J Clin Psychopharmacol
, vol.18
, pp. 19-25
-
-
Khan, A.1
Upton, G.V.2
Rudolph, R.L.3
-
31
-
-
0031909995
-
Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients
-
Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998;47:55-62
-
(1998)
J Affect Disord
, vol.47
, pp. 55-62
-
-
Feighner, J.P.1
Entsuah, A.R.2
McPherson, M.K.3
-
32
-
-
0029951845
-
Drug-drug interactions involving antidepressants: Focus on venlafaxine
-
Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16(3, suppl 2):37S-53S
-
(1996)
J Clin Psychopharmacol
, vol.16
, Issue.3 SUPPL. 2
-
-
Ereshefsky, L.1
-
33
-
-
80053070250
-
The etiologic featiftes-of depression in adults
-
Council on Scientific Affairs, American Medical Association. The etiologic featiftes-of depression in adults. Arch Earn Med 1993;2:76-84
-
(1993)
Arch Earn Med
, vol.2
, pp. 76-84
-
-
-
34
-
-
0030456961
-
Recognizing and treating the patient with somatic manifestations of depression?
-
De WesterJN. Recognizing and treating the patient with somatic manifestations of depression? J Earn Pract 1996;43(suppl 6):S3-S15
-
(1996)
J Earn Pract
, vol.43
, Issue.6 SUPPL.
-
-
De Wester, J.N.1
-
35
-
-
0027510643
-
The de facto US mental and addictive disorders service system: Epidemiologie Catchment Area prospective 1-year prevalence rate of disorders and services
-
Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system: Epidemiologie Catchment Area prospective 1-year prevalence rate of disorders and services. Arch Gen Psychiatry 1993;50:85-94
-
(1993)
Arch Gen Psychiatry
, vol.50
, pp. 85-94
-
-
Regier, D.A.1
Narrow, W.E.2
Rae, D.S.3
-
36
-
-
84943210661
-
Common mental disorders and disability across cultures: Results from the WHO Collaborative Study on Psychological Problems in General Care
-
Ormel J, VonKorff M, Ustun TB et al. Common mental disorders and disability across cultures: results from the WHO Collaborative Study on Psychological Problems in General Care. JAMA 1994;272: 1741-1748
-
(1994)
JAMA
, vol.272
, pp. 1741-1748
-
-
Ormel, J.1
Vonkorff, M.2
Ustun, T.B.3
-
37
-
-
0028308789
-
The prevalence and distribution of major depression in a national comjnuflitjl sample: The National Comorbidity Survey
-
Blazer DG, Kessler RC, McGonagle KA, et al. The prevalence and distribution of major depression in a national comjnuflitjl sample: the National Comorbidity Survey. Am J Psychiatry 1994;15:l
-
(1994)
Am J Psychiatry
, vol.15
-
-
Blazer, D.G.1
Kessler, R.C.2
McGonagle, K.A.3
-
38
-
-
52849127657
-
The major depression: Cross-national comparisons
-
Cross-National Collaborative Group. The major depression: cross-national comparisons. JAMA 1992;258:309-131
-
(1992)
JAMA
, vol.258
, pp. 309-1131
-
-
-
39
-
-
0028597871
-
Therapeutic considerations in treating depression in the elderly
-
Dunner DL. Therapeutic considerations in treating depression in the elderly. J Clin Psychiatry 1994;55( 12, suppl):48-58
-
(1994)
J Clin Psychiatry
, vol.55
, Issue.12 SUPPL.
, pp. 48-58
-
-
Dunner, D.L.1
-
40
-
-
0028607973
-
Recognition and treatment of depressiort-in a prirfiafy care setting
-
Montano CB. Recognition and treatment of depressiort-in a prirfiafy care setting. J Clin Psychiatry 1994;55(12, suppl): 18-34
-
(1994)
J Clin Psychiatry
, vol.55
, Issue.12 SUPPL.
, pp. 18-34
-
-
Montano, C.B.1
-
42
-
-
0031033949
-
Rational drug use in the treatment of depression
-
Cohen LJ. Rational drug use in the treatment of depression. PharmacQ/i therapy 1997;17:45-61
-
(1997)
PharmacQ/i Therapy
, vol.17
, pp. 45-61
-
-
Cohen, L.J.1
-
43
-
-
0028918951
-
Health care costs associated with depressive and anxiety disorders in primary care
-
Simon G, Ormel J, VonKorff M, et al. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 1995; 152:352-357
-
(1995)
Am J Psychiatry
, vol.152
, pp. 352-357
-
-
Simon, G.1
Ormel, J.2
Vonkorff, M.3
-
44
-
-
0028149443
-
Antidepressant drugs
-
Frazer A. Antidepressant drugs. Depression 1994;2:1-19
-
(1994)
Depression
, vol.2
, pp. 1-19
-
-
Frazer, A.1
-
45
-
-
0028272935
-
Use of minor tranquilizers and antidepressant medications by depressed outpatients: Results from the Medical Outcomes Study
-
Wells KB, Katon W Rogers B, et al. Use of minor tranquilizers and antidepressant medications by depressed outpatients: results from the Medical Outcomes Study. Am J Psychiatry 1994;151:694-700
-
(1994)
Am J Psychiatry
, vol.151
, pp. 694-700
-
-
Wells, K.B.1
Katon, W.2
Rogers, B.3
-
46
-
-
0028560322
-
Guidelines for the long-term treatment of depression
-
Hirschfeld RMA. Guidelines for the long-term treatment of depression. J Clin Psychiatry 1994;55(12, suppl):61-69
-
(1994)
J Clin Psychiatry
, vol.55
, Issue.12 SUPPL.
, pp. 61-69
-
-
Hirschfeld, R.M.A.1
-
47
-
-
0027406598
-
Comparison of full-dose versus halfdose pharmacotherapy in the maintenance treatment of recurrent depression
-
Frank E, Kupfer DJ, Perel JM, et al. Comparison of full-dose versus halfdose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993;27:139-145
-
(1993)
J Affect Disord
, vol.27
, pp. 139-145
-
-
Frank, E.1
Kupfer, D.J.2
Perel, J.M.3
-
48
-
-
0030727889
-
Citalopram: A review of its pharmacology, clinical efficacy and tolerability in the treatment of depression
-
Noble S, Benfield P. Citalopram: a review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs 1997; 8:410-431
-
(1997)
CNS Drugs
, vol.8
, pp. 410-431
-
-
Noble, S.1
Benfield, P.2
-
49
-
-
52849113667
-
Central nervous system drugs
-
St. Louis, Mo: Facts and Comparisons
-
Central nervous system drugs. In: Drug Facts and Comparisons, 1999 ed. St. Louis, Mo: Facts and Comparisons; 1998:1603
-
(1998)
Drug Facts and Comparisons, 1999 Ed.
, pp. 1603
-
-
-
50
-
-
0022448068
-
Citalopram: Clinical effect pro-file in comparison with clomipramine: a controlled multicenter study
-
Danish University Antidepressant Group. Citalopram: clinical effect pro-file in comparison with clomipramine: a controlled multicenter study. Psychopharmacology 1986;90:131-138
-
(1986)
Psychopharmacology
, vol.90
, pp. 131-138
-
-
-
51
-
-
0025217229
-
Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study
-
Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18:289-299
-
(1990)
J Affect Disord
, vol.18
, pp. 289-299
-
-
-
52
-
-
0029891688
-
Dose-response relationship with venlafaxine
-
Kelsey JE. Dose-response relationship with venlafaxine. J Clin Psychopharmacol 1996;16(suppl 2):21S-28S
-
(1996)
J Clin Psychopharmacol
, vol.16
, Issue.2 SUPPL.
-
-
Kelsey, J.E.1
-
53
-
-
0028075556
-
The role of venlafaxine in rational antidepressant therapy
-
Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994;55(9, suppl A):62-70
-
(1994)
J Clin Psychiatry
, vol.55
, Issue.9 SUPPL. A
, pp. 62-70
-
-
Feighner, J.P.1
-
54
-
-
0028855974
-
Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia
-
Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-458
-
(1995)
J Clin Psychiatry
, vol.56
, pp. 450-458
-
-
Guelfi, J.D.1
White, C.2
Hackett, D.3
-
55
-
-
0030014201
-
Antidepressant options: Venlafaxine in perspective
-
Thase ME. Antidepressant options: venlafaxine in perspective. J Clin Psychopharmacol 1996;16(3, suppl 2):10S-20S
-
(1996)
J Clin Psychopharmacol
, vol.16
, Issue.3 SUPPL. 2
-
-
Thase, M.E.1
-
56
-
-
0031916752
-
Drug interactions: Friend or foe?
-
Jefferson JW. Drug interactions: friend or foe? J Clin Psychiatry 1998;59 (suppl 4):37-4T7
-
(1998)
J Clin Psychiatry
, vol.59
, Issue.4 SUPPL.
-
-
Jefferson, J.W.1
-
57
-
-
4243547562
-
Depressive disorders
-
DiPiro JT, Talbert RE, Yee GC, et al, eds. Stamford, Conn: Appleton & Eange;
-
Wells BG, Mandos EA. Depressive disorders. In: DiPiro JT, Talbert RE, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. Stamford, Conn: Appleton & Eange; 1997:1395-1417
-
(1997)
Pharmacotherapy: A Pathophysiologic Approach
, pp. 1395-1417
-
-
Wells, B.G.1
Mandos, E.A.2
-
58
-
-
0029829648
-
Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders
-
Brown C, Schulberg HC, Madonia MJ, et al. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry 1996;153:1293-1300
-
(1996)
Am J Psychiatry
, vol.153
, pp. 1293-1300
-
-
Brown, C.1
Schulberg, H.C.2
Madonia, M.J.3
-
59
-
-
0015385801
-
The prognosis of affective disorders: The differentiation of anxiety states from depressive illnesses
-
Schapira K, Roth M, Kerr TA, et al. The prognosis of affective disorders: the differentiation of anxiety states from depressive illnesses. Br J Psychiatry 1972;121:175-181
-
(1972)
Br J Psychiatry
, vol.121
, pp. 175-181
-
-
Schapira, K.1
Roth, M.2
Kerr, T.A.3
-
60
-
-
0032697699
-
Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys
-
Kessler RC, DuPont RE, Berglund P, et al. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999;156:1915-1923
-
(1999)
Am J Psychiatry
, vol.156
, pp. 1915-1923
-
-
Kessler, R.C.1
Dupont, R.E.2
Berglund, P.3
-
61
-
-
0030434199
-
Comorbid depression and anxiety spectrum disorders
-
Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety 1996;4:160-168
-
(1996)
Depress Anxiety
, vol.4
, pp. 160-168
-
-
Gorman, J.M.1
-
62
-
-
0030469377
-
Treating comorbid depression and anxiety
-
Kuzel RJ. Treating comorbid depression and anxiety. J Earn Pract 1996;43 (6, suppl):S45-S53
-
(1996)
J Earn Pract
, vol.43
, Issue.6 SUPPL.
-
-
Kuzel, R.J.1
-
63
-
-
0029162334
-
Anxiety symptom relief in depression treatment outcomes
-
Keller MB, Hanks DE. Anxiety symptom relief in depression treatment outcomes. J Clin Psychiatry 1995;56(suppl 6):22-29
-
(1995)
J Clin Psychiatry
, vol.56
, Issue.6 SUPPL.
, pp. 22-29
-
-
Keller, M.B.1
Hanks, D.E.2
-
64
-
-
0031724183
-
A controlled prospective, 1-year trial of citalopram in the treatment of panic disorder
-
Eepola UM, Wade AG, Eeinonen EV, et al. A controlled prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998;59:528-534
-
(1998)
J Clin Psychiatry
, vol.59
, pp. 528-534
-
-
Eepola, U.M.1
Wade, A.G.2
Eeinonen, E.V.3
-
65
-
-
0030724916
-
Citalopram in the treatment of obsessive-compulsive disorder: An open pilot study
-
Kojjsnen H, Eepola U, Eeinonen E, et al. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand 1997,96:343-346
-
(1997)
Acta Psychiatr Scand
, vol.96
, pp. 343-346
-
-
Kojjsnen, H.1
Eepola, U.2
Eeinonen, E.3
-
66
-
-
0030480395
-
Venlafaxine for panic disorder: Results from a double-blind, placebo-controlled study
-
66: Pollack fptE.Worthington JJ III, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull S96;32:667-670
-
(1996)
Psychopharmacol Bull
, vol.32
, pp. 667-670
-
-
Pollack, E.1
Worthington III, J.J.2
Otto, M.W.3
-
67
-
-
0030470480
-
An open trial of nefazodone in adult patients with generalized anxiety disorder
-
Hedges.-D;-4, Rennljerr FW, Strong RE, et al. An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol Bull 1996;32:671-676.
-
(1996)
Psychopharmacol Bull
, vol.32
, pp. 671-676
-
-
Hedges, D.1
Rennljerr, F.W.2
Strong, R.E.3
-
68
-
-
0028800848
-
Efficacy and tolerability of serotonin transport inhibito obsessive-compulsive disorder: A metaanalysis
-
Greist JH, Jeffer Son JW Obak KA, et al. Efficacy and tolerability of serotonin transport inhibito obsessive-compulsive disorder: a metaanalysis. Arch Gen Psychiatry 995;52;53-60
-
(1995)
Arch Gen Psychiatry
, vol.52
, pp. 53-60
-
-
Greist, J.H.1
Jeffer Son, J.W.2
Obak, K.A.3
-
69
-
-
0030988949
-
Antidepressants in panisfajsorder
-
Jefferson JW. Antidepressants in panisfajsorder. J Clin Psychiatry 1997;58 (suppl 2):20-25
-
(1997)
J Clin Psychiatry
, vol.58
, Issue.2 SUPPL.
, pp. 20-25
-
-
Jefferson, J.W.1
-
70
-
-
9544233539
-
Chronological milestones to guide drug change: When should clinicians.switch antidepressants?
-
Quitkin FM, McGrath PJ, Stewart JW, Chronological milestones to guide drug change: when should clinicians.switch antidepressants? Arch Gen Psychiatry 1996;53:785-792
-
(1996)
Arch Gen Psychiatry
, vol.53
, pp. 785-792
-
-
Quitkin, F.M.1
McGrath, P.J.2
Stewart, J.W.3
-
71
-
-
0029948564
-
Clinical evaluation of venlafaxine
-
Ballenger JC. Clinical evaluation of venlafaxine.jj ClinPsychopharmacol 1996;16(suppl 2):29S-36S
-
(1996)
Jj ClinPsychopharmacol
, vol.16
, Issue.2 SUPPL.
-
-
Ballenger, J.C.1
|